Ajay K. Gopal
M.D., Emory University, Medicine, 1993.
B.S., Duke University, Zoology, 1989.
American Association for Cancer Research
American Society for Clinical Oncology
American Society of Hematology
2003-2007, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
2003-2007, Assistant Professor, University of Washington, School of Medicine, Medicine, Oncology
1997-2000, Fellow in Medical Oncology, University of Washington, School of Medicine, Medicine, Oncology
1993-1996, Resident in Internal Medicine, Duke University, Duke University Medical Center, Medicine
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2014.
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine.. 2014.
Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Aged ≥ 60 Years with B-Cell Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2014.
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.. British journal of haematology.. 2014.
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6.. 2013.
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20.. 2013.
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32.. 2013.
CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies.. Journal of clinical pharmacology. 53(8):866-77.. 2013.
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.. Nuclear medicine communications. 33(12):1225-31.. 2012.
Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.. The Korean journal of hematology. 47(1):8-16.. 2012.
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189.. 2012.
Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.. Best practice & research. Clinical haematology. 25(2):165-74.. 2012.
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.. Journal of clinical apheresis.. 2012.